One year after announcing its decision to sell off its microarray business, and still absent a buyer or partner, Nanogen is on track to stop selling arrays and supporting existing customers by the end of this year, according to a company official.
 
While the San Diego-based vendor has sold most of its NanoChip 400 microarray platform assets and inventory, it has retained the intellectual property related to the system, as well as the ability to use the arrays for internal R&D projects.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.